Skip to main content

Archived Comments for: Blood pressure control and components of the metabolic syndrome: the GOOD survey

Back to article

  1. Arterial Hypertension is under control if hepatic PPARs are well functioning.

    Sergio Stagnaro, Quantum Biophysical Semeiotics Research Laboratory

    9 December 2009

    from the clinical view-point, I agree with the data of this fascinating study. In fact, only when the lipid and glucose metabolism is under control, blood pressure can be in normal range. Now-a-days, the best method in assessing lipid and glucose metabolism is the bedside evaluation of liver PPARs (1-7). Accordingly, low caloric diet and regular physical exercise induced significant improvement in blood pressure, body mass index, waist-to-hip- circumference,without any change on drug prescription, but it brings about other paramount benifits (1). Let us consider, for instance, that one of the most active areas of metabolic research into potential treatments surrounds the role of nuclear receptors as a treatment target for both glucose and lipid metabolism. In addition, agonists of the peroxisome proliferator-activated receptor (PPAR) offer unique potential in several respects (See; Practical Applications: PPARS). PPAR agonists (such as fibrates, thiazolidinediones, coniugated-melatonin, according to Di Bella-Ferrari) have been shown to lower triglyceride and increase HDL-c, with a variable effect upon LDL-c blood levels. PPARs agonists have variable effects on the lipid profile, in addition to improving insulin sensitivity and blood glucose levels in patients with type 2 diabetes. Pre-clinical studies suggest that both PPARs and PPARs agonists have direct anti-atherogenic effects (1). Therefore, single agents that promote both PPARs and PPARs agonism could theoretically offer significant benefits in improving dyslipidaemia and reducing hyperglycaemia, and thus reduce these cardiovascular risk factors associated with type 2 diabetes and metabolic syndrome. Interestingly, PPAR physiological functioning proved to be useful and reliable to indicate clinically a normal glyco-lipidaemic metabolism, in agreement with other authors (2). Among a lot of biophysical-semeiotic methods (See above-mentioned website; Practical Applications), different in technical difficulty, but similarly reliable and useful in assessing peroxisome proliferator-activated receptors (PPARs) (3), I suggest two methods, based on melatonin and thyroide hormone secretion, which allow doctor to bed-side evaluate the activity of such nuclear receptors in individuals with Pre-Metabolic Syndrome (3-6). In a few words, PPARs are members of the nuclear receptor family that regulates the expression of genes that control fatty acid synthesis, storage, catabolism, as well as glucose homeostasis and insulin sensitivity, e.g., in the liver. PPARs bind as heterodimers with another member of the nuclear receptor family, the retinoid X receptor (RXR- ROR), stimulated also by melatonin (3-6), to peroxisome proliferator response elements (PPREs) in the P450 4A1 and 4A6 genes. In addition, recent data suggest that PPAR alpha and gamma activation decreases atherosclerosis progression not only by correcting metabolic disorders, but also through direct effects on the vascular wall (1-7). PPARs modulate the recruitment of leukocytes to endothelial cells, control the inflammatory response and lipid homeostasis of monocytes/macrophages and regulate inflammatory cytokine production by smooth muscle cells. In conclusion, Biophysical-Semeiotic Evaluating PPARs activity, described for the first time from clinical view-point, represents a paramount event in Preventive Medicine.

    1) Stagnaro Sergio. Bedside biophysical-semeiotic PPARs evaluation in glucose-lipid metabosism monitoring. Annals of Family Medicine 2007; 5: 14-20.
    2) Stagnaro Sergio. Reale Rischio Semeiotico Biofisico. I Dispositivi Endoarteriolari di Blocco neoformati, patologici, tipo I, sottotipo a) oncologico, e b) aspecifico. Ediz. Travel Factory,, Roma, Luglio 2009.
    3) Stagnaro Sergio. Pre-Metabolic Syndrome and Metabolic Syndrome: Biophysical-Semeiotic Viewpoint., 29 April, 2009.
    4) Stagnaro Sergio, Stagnaro-Neri Marina. Introduzione alla Semeiotica Biofisica. Il Terreno oncologico". Travel Factory SRL., Roma, 2004.
    5) Stagnaro S., Stagnaro-Neri M., La Melatonina nella Terapia del Terreno Oncologico e del "Reale Rischio" Oncologico. Ediz. Travel Factory, Roma, 2004.
    6) Stagnaro S., Stagnaro-Neri M., Le Costituzioni Semeiotico-Biofisiche.Strumento clinico fondamentale per la prevenzione primaria e la definizione della Single Patient Based Medicine. Ediz. Travel Factory, Roma, 2004.
    7) Stagnaro Sergio Biophysical-Semeiotic Bed-Side Evaluating PPARs Activity in Metabolic Syndrome. Cardiovascular Diabetology. (19 September 2005)

    Competing interests

    None declared